

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/011652

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K45/06 A61K31/585 A61K31/5415 A61K31/41 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 831 910 B (G.D. SEARLE &amp; CO) 21 November 2001 (2001-11-21)</p> <p>page 4, line 29 - line 30 page 15, line 3 - line 4 claim 11</p> <p>----- -/--</p>	<p>1,6,7, 12,13, 16,17</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

1 June 2005

Date of mailing of the international search report

- 9. 09. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/011652

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PITT B ET AL: "THE EFFECT OF SPIRONOLACTONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH SEVERE HEART FAILURE" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 341, no. 10, 2 September 1999 (1999-09-02), pages 709-717, XP008047312 ISSN: 0028-4793 page 1834, column 2, paragraph 2 - page 1835, column 1, paragraph 1 table 3</p>	<p>1-4,6-9, 11-14, 16,17</p>
X	<p>US 2003/162759 A1 (ROCHA RICARDO ET AL) 28 August 2003 (2003-08-28)</p> <p>page 5, column 1, paragraph 101 page 5, column 2, paragraph 107 claim 14</p>	<p>1,2,6-8, 12,13, 16,17</p>
X	<p>SAWATHIPARNICH PAIRUNYAR ET AL: "Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1." JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 88, no. 8, August 2003 (2003-08), pages 3867-3873, XP008047304 ISSN: 0021-972X page 3868, column 2, paragraph 4 - page 3869, column 2, paragraph 4</p>	<p>1,2,6,7, 12,13, 16,17</p>
X	<p>US 2002/156057 A1 (BUBIEN JAMES K) 24 October 2002 (2002-10-24)</p> <p>claims 1-4</p>	<p>1,2,6-8, 12,13, 16,17</p>

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/011652

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 12 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

1-17 (all partially)

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-17 all partially

A combination for the treatment or prevention of hypertension comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

2. claims: 1-17 all partially

A combination for the treatment or prevention of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

3. claims: 1-17 all partially

A combination for the treatment or prevention of diabetic cardiac myopathy comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

4. claims: 1-17 all partially

A combination for the treatment or prevention of supra ventricular and ventricular arrhythmias comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

5. claims: 1-17 all partially

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A combination for the treatment or prevention of atrial fibrillation comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 6. claims: 1-17 all partially

A combination for the treatment or prevention of atrial flutter comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 7. claims: 1-17 all partially

A combination for the treatment or prevention of detrimental vascular remodelling comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 8. claims: 1-17 all partially

A combination for the treatment or prevention of myocardial infarction and its sequelae comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 9. claims: 1-17 all partially

A combination for the treatment or prevention of atherosclerosis comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 10. claims: 1-17 all partially

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A combination for the treatment or prevention of unstable or stable angina comprising:

- (i) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 11. claims: 1-17 all partially

A combination for the treatment or prevention of renal insufficiency comprising:

- (i) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 12. claims: 1-17 all partially

A combination for the treatment or prevention of angina pectoris comprising:

- (i) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 13. claims: 1-17 all partially

A combination for the treatment or prevention of diabetes comprising:

- (i) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 14. claims: 1-17 all partially

A combination for the treatment or prevention of secondary aldosteronism comprising:

- (i) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 15. claims: 1-17 all partially

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A combination for the treatment or prevention of primary and secondary pulmonary hypertension comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 16. claims: 1-17 all partially

A combination for the treatment or prevention of renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and renal vascular hypertension comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 17. claims: 1-17 all partially

A combination for the treatment or prevention of diabetic retinopathy comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 18. claims: 1-17 all partially

A combination for the treatment or prevention of migraine comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## 19. claims: 1-17 all partially

A combination for the treatment or prevention of peripheral vascular disease comprising:  
(I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,  
(ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally  
(iii) an angiotensin receptor blocker (ARB)  
---

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 20. claims: 1-17 all partially

A combination for the treatment or prevention of Raynaud's disease comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 21. claims: 1-17 all partially

A combination for the treatment or prevention of luminal hyperplasia comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 22. claims: 1-17 all partially

A combination for the treatment or prevention of Alzheimer's disease comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 23. claims: 1-17 all partially

A combination for the treatment or prevention of glaucoma comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---

## 24. claims: 1-17 all partially

A combination for the treatment or prevention of stroke comprising:

- (I) an aldosterone receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a diuretic or a pharmaceutically acceptable salt thereof, and optionally
- (iii) an angiotensin receptor blocker (ARB)

---



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/011652

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0831910	B	01-04-1998	AT 209047 T 15-12-2001
		AU 725689 B2 19-10-2000	
		AU 6157796 A 30-12-1996	
		BR 9609066 A 26-01-1999	
		DE 69617235 D1 03-01-2002	
		DE 69617235 T2 25-07-2002	
		DK 831910 T3 21-05-2002	
		EP 0831910 A1 01-04-1998	
		IL 122242 A 24-07-2001	
		JP 11507627 T 06-07-1999	
		NO 975741 A 29-01-1998	
		NZ 310730 A 26-01-2001	
		PL 324001 A1 27-04-1998	
		RO 118046 B1 30-01-2003	
		CA 2224079 A1 19-12-1996	
		CN 1192697 A ,C 09-09-1998	
		CN 1522701 A 25-08-2004	
		CZ 9703850 A3 17-06-1998	
		ES 2167571 T3 16-05-2002	
		PT 831910 T 31-05-2002	
		RU 2166330 C2 10-05-2001	
		WO 9640257 A1 19-12-1996	
		US 6653306 B1 25-11-2003	
US 2003162759	A1	28-08-2003	AU 1604001 A 24-12-2001
			AU 1658001 A 24-12-2001
			AU 8080401 A 13-02-2002
			CA 2407699 A1 20-12-2001
			CA 2416152 A1 07-02-2002
			CN 1455667 A 12-11-2003
			EP 1289507 A1 12-03-2003
			EP 1368009 A2 10-12-2003
			JP 2004503495 T 05-02-2004
			JP 2004518611 T 24-06-2004
			WO 0195892 A1 20-12-2001
			WO 0195893 A1 20-12-2001
			WO 0209683 A2 07-02-2002
			US 2003096798 A1 22-05-2003
			US 2003191100 A1 09-10-2003
			US 2003203884 A1 30-10-2003
			US 2004102424 A1 27-05-2004
			US 2003125312 A1 03-07-2003
US 2002156057	A1	24-10-2002	CA 2482124 A1 31-10-2002
			WO 02085367 A1 31-10-2002